Business
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026 Received Orphan Designation for CMP-002 by the European Medicines Agency (EMA) Entered into collaboration with CURE SYNGAP1 to support ProMMiS, a natural history study to advance understanding of SYNGAP1 related disorder Cash runway expected into 2028, with $99 million in cash
About this update from Camp4 Therapeutics Corporation
[{"type":"image","alt":"CAMP4 Therapeutics","displaySize":"","headline":null,"caption":"CAMP4 Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/21702dc1d4660b70780cbc865b3cc20b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eH8rnGa.odLogUxnWG9sUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/21702dc1d4660b70780cbc865b3cc20b","width":300,"height":94},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/eH8rnGa.odLogUxnWG9sUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/21702dc1d4660b70780cbc865b3cc20b","width":300,"height":94}},"lazy":false},{"type":"text","content":"Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026 ","length":222,"tagName":"p"},{"type":"text","content":"Received Orphan Designation for CMP-002 by the European Medicines Agency (EMA)","length":78,"tagName":"p"},{"type":"text","content":"Entered into collaboration with CURE SYNGAP1 to support ProMMiS, a natural history study to advance understanding of SYNGAP1 related disorder","length":141,"tagName":"p"},{"type":"text","content":"Cash runway expected into 2028, with $99 million in cash and cash equivalents as of 3/31/26","length":91,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate highlights.","length":466,"tagName":"p"},{"type":"text","content":""We have made significant progress year-to-date against our goal of bringing a potential first-in-class treatment for SYNGAP1-related disorder into the clinic,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. “We submitted our first regulatory filing for CMP-002 in Australia which positions us to initiate a global f...